뒤로
Rakovina Therapeutics Inc(RKVTF) 가격
RKVTF 주가 차트
RKVTF 수입
Rakovina Therapeutics Inc
$0.09
10.85%
$0
종가: Jan 23, 16:00:00 GMT-5
$0.1
3.92%
$0
애프터마켓: Jan 23, 20:00:00 GMT-5
Earnings FAQ
RKVTF의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Rakovina Therapeutics Inc RKVTF의 지난 분기 매출 실적은 어땠나요?
Rakovina Therapeutics Inc의 매출 추정치는 얼마인가요?
Rakovina Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Rakovina Therapeutics Inc는 언제 수익을 보고하나요?
Rakovina Therapeutics Inc의 예상 수익은 얼마인가요?
Rakovina Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.0868
시가
$0.0931
일일 범위
$0.0911 - $0.1
52주 범위
$0.065 - $3.2
거래량
--
평균 거래량
6.7K
EPS(TTM)
-0.41
배당수익률
--
시가총액
$2.1M
RAKOVINA THERAPEUTICS INC란 무엇인가요?
Rakovina Therapeutics, Inc. focuses on the development of new cancer treatments based on novel DNA-damage response technologies. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2020-02-07. The company is focused on the development of cancer treatments based on deoxyribonucleic acid (DNA)-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking and Enki platforms. Its drug development pipeline includes kt-2000AI and kt-3000 series. The company is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.